Category: Bez kategorii
-
Polpharma API Business Unit (API BU) completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.
As of September 26, 2019, EMA’s Human Medicines Committee (CHMP) requested as a matter of precaution…
-
Why particles size is important in pharmaceutical industry? Is it really problematic?
In the pharmaceutical industry, particle size has become one of the key aspects in the development of the active…